USP22 transcriptional activity is negatively regulated by the histone deacetylase inhibitor trichostatin A

Xiong,Jianjun; Xu,Xiaoyuan; Zhou,Xiaou; Liu,Jianyun; Gong,Zhen; Wu,Ping; Li,Weidong

doi:10.3892/mmr.2014.2666

USP22 transcriptional activity is negatively regulated by the histone deacetylase inhibitor trichostatin A

Authors:
- Jianjun Xiong
- Xiaoyuan Xu
- Xiaou Zhou
- Jianyun Liu
- Zhen Gong
- Ping Wu
- Weidong Li
View Affiliations

Affiliations: Jiangxi Province Key Laboratory of Systems Biomedicine, Jiujiang University, Jiujiang, Jiangxi 332000, P.R. China, College of Basic Medical Science, Jiujiang University, Jiujiang, Jiangxi 332000, P.R. China
Published online on: October 15, 2014 https://doi.org/10.3892/mmr.2014.2666
Pages: 3343-3347

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The ubiquitin‑specific protease 22 (USP22) gene is overexpressed in the majority of types of cancer cells, and has been implicated in tumorigenesis. However, the mechanisms that regulate its expression remain unclear. The results of the present study demonstrated that the expression of USP22 is negatively regulated by trichostatin A (TSA), a classical histone deacetylase inhibitor. Furthermore, TSA was revealed to interfere with the binding of RNA polymerase II to the USP22 promoter, directly suppressing its transcription. In addition, the overexpression of USP22 was observed to attenuate TSA‑induced apoptosis in HeLa cells. To the best of our knowledge, these results provide the first insight into the regulation of the USP22 gene by antitumor drugs and into the mechanisms underlying the anticancer activity of TSA.

View Figures

View References

1	Lee HJ, Kim MS, Shin JM, Park TJ, Chung HM and Baek KH: The expression patterns of deubiquitinating enzymes, USP22 and Usp22. Gene Expr Patterns. 6:277–284. 2006. View Article : Google Scholar : PubMed/NCBI
2	Zhang XY, Varthi M, Sykes SM, et al: The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell. 29:102–111. 2008. View Article : Google Scholar : PubMed/NCBI
3	Zhao Y, Lang G, Ito S, et al: A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing. Mol Cell. 29:92–101. 2008. View Article : Google Scholar
4	Lin Z, Yang H, Kong Q, et al: USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development. Mol Cell. 46:484–494. 2012. View Article : Google Scholar : PubMed/NCBI
5	Atanassov BS and Dent SY: USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1. EMBO Rep. 12:924–930. 2011. View Article : Google Scholar : PubMed/NCBI
6	Glinsky GV: Death-from-cancer signatures and stem cell contribution to metastatic cancer. Cell Cycle. 4:1171–1175. 2005. View Article : Google Scholar : PubMed/NCBI
7	Glinsky GV, Berezovska O and Glinskii AB: Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 115:1503–1521. 2005. View Article : Google Scholar : PubMed/NCBI
8	Kouzarides T: Acetylation: a regulatory modification to rival phosphorylation? EMBO J. 19:1176–1179. 2000. View Article : Google Scholar : PubMed/NCBI
9	Kawai H, Li H, Avraham S, Jiang S and Avraham HK: Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. Int J Cancer. 107:353–358. 2003. View Article : Google Scholar : PubMed/NCBI
10	Duan H, Heckman CA and Boxer LM: Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol. 25:1608–1619. 2005. View Article : Google Scholar : PubMed/NCBI
11	Hsu YF, Sheu JR, Lin CH, et al: Trichostatin A and sirtinol suppressed survivin expression through AMPK and p38MAPK in HT29 colon cancer cells. Biochim Biophys Acta. 1820:104–115. 2012. View Article : Google Scholar : PubMed/NCBI
12	Han JW, Ahn SH, Kim YK, et al: Activation of p21(WAF1/Cip1) transcription through Sp1 sites by histone deacetylase inhibitor apicidin: involvement of protein kinase C. J Biol Chem. 276:42084–42090. 2001. View Article : Google Scholar : PubMed/NCBI
13	Xiong J, Che X, Li X, Yu H, Gong Z and Li W: Cloning and characterization of the human USP22 gene promoter. PLoS One. 7:e527162012. View Article : Google Scholar : PubMed/NCBI
14	Sakamoto S, Potla R and Larner AC: Histone deacetylase activity is required to recruit RNA polymerase II to the promoters of selected interferon-stimulated early response genes. J Biol Chem. 279:40362–40367. 2004. View Article : Google Scholar
15	Zhang Y and Dufau ML: Silencing of transcription of the human luteinizing hormone receptor gene by histone deacetylase-mSin3A complex. J Biol Chem. 277:33431–33438. 2002. View Article : Google Scholar : PubMed/NCBI
16	Xiong Y, Dowdy SC, Podratz KC, et al: Histone deacetylase inhibitors decrease DNA methyltransferase-3B messenger RNA stability and down-regulate de novo DNA methyltransferase activity in human endometrial cells. Cancer Res. 65:2684–2689. 2005. View Article : Google Scholar
17	Chen WY, Weng JH, Huang CC and Chung BC: Histone deacetylase inhibitors reduce steroidogenesis through SCF-mediated ubiquitination and degradation of steroidogenic factor 1 (NR5A1). Mol Cell Biol. 27:7284–7290. 2007. View Article : Google Scholar
18	Ovaa H, Kessler BM, Rolen U, Galardy PJ, Ploegh HL and Masucci MG: Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells. Proc Natl Acad Sci USA. 101:2253–2258. 2004. View Article : Google Scholar : PubMed/NCBI
19	Waby JS, Chirakkal H, Yu C, et al: Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line. Mol Cancer. 9:2752010. View Article : Google Scholar : PubMed/NCBI
20	Suzuki T, Kimura A, Nagai R and Horikoshi M: Regulation of interaction of the acetyltransferase region of p300 and the DNA-binding domain of Sp1 on and through DNA binding. Genes Cells. 5:29–41. 2000. View Article : Google Scholar : PubMed/NCBI
21	Furumai R, Ito A, Ogawa K, et al: Histone deacetylase inhibitors block nuclear factor-kappaB-dependent transcription by interfering with RNA polymerase II recruitment. Cancer Sci. 102:1081–1087. 2011. View Article : Google Scholar
22	Choi KH, Basma H, Singh J and Cheng PW: Activation of CMV promoter-controlled glycosyltransferase and beta-galactosidase glycogenes by butyrate, tricostatin A, and 5-aza-2′-deoxycytidine. Glycoconj J. 22:63–69. 2005.PubMed/NCBI
23	Armour SM, Bennett EJ, Braun CR, et al: A high-confidence interaction map identifies SIRT1 as a mediator of acetylation of USP22 and the SAGA coactivator complex. Mol Cell Biol. 33:1487–1502. 2013. View Article : Google Scholar